Clinuvel Pharmaceuticals Ltd
ASX:CUV
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Price:
14.86 AUD
Market Closed
Updated:
May 5, 2024
Clinuvel Pharmaceuticals Ltd
Cash from Financing Activities
|
Clinuvel Pharmaceuticals Ltd
Cash from Financing Activities Peer Comparison
Comparables:
IMM
MSB
CSL
TLX
PYC
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Cash from Financing Activities
-AU$2.7m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Immutep Ltd
ASX:IMM
|
Cash from Financing Activities
AU$76m
|
CAGR 3-Years
15%
|
CAGR 5-Years
29%
|
CAGR 10-Years
19%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash from Financing Activities
$67.8m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Cash from Financing Activities
-$1.6B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-8%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash from Financing Activities
AU$10.2m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash from Financing Activities
AU$28.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
27%
|
CAGR 10-Years
22%
|
See Also
What is Clinuvel Pharmaceuticals Ltd's Cash from Financing Activities?
Cash from Financing Activities
-2.7m
AUD
-2.7m
AUD
Based on the financial report for Dec 31, 2023, Clinuvel Pharmaceuticals Ltd's Cash from Financing Activities amounts to -2.7m AUD.
What is Clinuvel Pharmaceuticals Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-23%
-23%
Over the last year, the Cash from Financing Activities growth was -20%. The average annual Cash from Financing Activities growth rates for Clinuvel Pharmaceuticals Ltd have been -22% over the past three years , -23% over the past five years .
You don't have any saved screeners yet
